



05-24-04

IFN  
PATENT  
674509-2052.1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Nielsen et al.  
U.S. Serial No. : 10/699,377  
Filing Date : October 31, 2003  
For : COMPOSITION  
Art Unit : 1761

745 Fifth Avenue  
New York, NY 10151

**EXPRESS MAIL**

Mailing Label Number: EV 286858522 US

Date of Deposit: May 21, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: **Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Charles B. Jackson

(Typed or printed name of person mailing paper or fee)

Charles B. Jackson

(Signature of person mailing paper or fee)

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully drawn to the enclosed documents listed on the accompanying PTO Form 1449.

As this Information Disclosure Statement is being filed before the mailing of the first Office Action, it is believed that no fee is required for entry of this paper. However, the

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: Dale B. Schenk

Application No./Patent No.: 09/585,817 Filed/Issue Date: June 1, 2000

Entitled: Prevention and Treatment of Amyloidogenic Disease

Neuralab Limited a corporation

(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest; or
2.  an assignee of less than the entire right, title and interest.  
The extent (by, percentage) of its ownership interest is \_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Dale B. Schenk To: Elan Pharmaceuticals, Inc.

The document was recorded in the United States Patent and Trademark Office at Reel 012230, Frame 0877, or for which a copy thereof is attached.

2. From: Elan Pharmaceuticals, Inc. To: Neuralab Limited

The document was recorded in the United States Patent and Trademark Office at Reel 012230, Frame 0885, or for which a copy thereof is attached.

3. From: Elan Pharmaceuticals, Inc. To: Neuralab Limited (Nunc Pro Tunc)

The document was recorded in the United States Patent and Trademark Office at Reel 012230, Frame 0893, or for which a copy thereof is attached.

 Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

FEBRUARY 28, 2002

Date

Kevin Insley

Typed or printed name

Kevin Insley

Signature

Vice President

Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.